NIH Extends $2M Non-Dilutive Grant for Daré Bioscience's Preterm Birth Drug Candidate
Summary
Daré Bioscience announced it received an extended Notice of Award from the NIH, securing approximately $2.0 million in non-dilutive funding for its DARE-PTB1 program. This extension specifically covers the second tranche of approximately $1.0 million through November 2026, ensuring continued support for the Phase 1 clinical study of its novel intravaginal ring for preterm birth prevention. For a company with a market capitalization of around $20 million, this $2 million in non-dilutive funding is highly material, representing a significant portion of its value and substantially de-risking the development of a key pipeline asset without shareholder dilution. This news is new and not reflected in the recent SEC filings. Traders will monitor the progress of the DARE-PTB1 clinical study and any further updates on its development.
At the time of this announcement, DARE was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.6M. The 52-week trading range was $1.42 to $9.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.